Molybdenum for Asthma
There is no reliable evidence that molybdenum supplements treat or prevent asthma. The only basis is an unproven mechanistic hypothesis about sulfite-sensitive asthma, with no modern controlled trials.
Why this grade7-layer evidence engine
The engine grades this Unverified (Tier U, Insufficient Evidence). The single piece of human data, a 1990 cross-sectional study of 18 people (PMID 2643005), only links low sulfite oxidase activity to sulfite sensitivity; it tested no molybdenum supplement and was rated low quality. All evidence is pre-1995, very small, and uncontrolled, with no modern trial to replicate it.
Regulators treat molybdenum purely as an essential trace mineral, not an asthma therapy. The US FDA sets only a 45 mcg Daily Value, the EU EFSA approves just one claim (it 'contributes to normal sulphur amino acid metabolism'), the UK NHS says a normal diet supplies all you need, and the WHO defines safe intake ranges without any asthma indication.
No major clinic or asthma authority endorses it. The NIH Office of Dietary Supplements states plainly that 'Molybdenum is not a standard treatment for any disease or disorder,' while Mayo Clinic, Cleveland Clinic, Harvard, and the GINA/ATS asthma guidelines do not address it at all. The sulfite-oxidase rationale is a fringe hypothesis limited to a narrow subgroup and remains clinically unproven.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.396
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 僅有 E10 級證據 (cohort/animal/mechanism)，不足以下結論
- tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative；實際 E10)
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status